Quercetin (QUE) and its water-soluble form сorvitin are medicinally important members of the flavonoid family and the most prominent dietary antioxidants. Numerous pharmacological effects of quercetin include protection against diseases, such as atherosclerosis, myocardial infarction, and cerebrovascular disea ses. Corvitin modulates liver blood flow but its effects on liver lipid metabolism have not been understood. We investigated the influence of corvitin (2.5, 5, 10 mg/kg) on the formation and secretion of cholesterol (Chol), cholesterol esters (EChol), phospholipids (PLs), free fatty acids (FFAs), and triglycerides (TGs) into the bile. Secreted bile was collected during 2.5 h of the experiment. Lipid fractions of the bile were separated by thin-layer chromatography. We defined that administration of corvitin caused a significant (P < 0.05-0.001) increase in levels of all studied lipid components of bile. At a dose of 2.5 and 5 mg/kg corvitin increased bile content of Chol, PLs and FFAs,and at a dose of 10 mg/kg had the largest effect on the total production of EChol and TGs. We concluded that corvitin activates the liver lipids metabolism and processes of bile formation.
B ile formation is a unique function of the liver , which is vital to the survival of the organism . The bile is a complex aqueous product , which contains bile acids (BAs) and nu merous lipid components, including, phospholi pids (PLs), free cholesterol (Chol), cholesterol es ters (EChols), and to a lesser extent free fatty acids (FFAs) and triglycerides (TGs). The liver actively eliminates Chol by secreting of it into the bile either directly or after its conversion into BAs, thereby regu lating its levels in the body. Therefore, Chol balan ceisachievedbymodulatingitsesterification, biosynthesis, and excretion [1] . The liver is the cen tral organ involved in the metabolism of lipids, which are the key source of energy in the body and might cause various pathological conditions. In particular, the accumulation of lipids in hepatocytes results in disorders of lipid metabolism and may be a stimulus to many chronic metabolic diseases, especially fatty liver degeneration, which leads to hepatic cirrhosis, hepatic failure, and hepatocellular carcinoma, in the absence of alcohol abuse [2] . Hepatoprotective drugs applied in clinical practice often have undesirable sideeffects,especiallyiftheyareusedchronicallyor subchronically. Based on this, there has been interest ofscientistsandcliniciansinfindingvariousnatu ral compounds with hepatoprotective properties that would be combined with a lack of toxicity, harmful sideeffectsonthebodyandlowcost.
Hyperlipidemia is one of the major risk factors for heart diseases, including atherosclerosis, myo cardial infarction, and cerebrovascular diseases [3] . Nowadays, in developing countries, hyperlipidemia and atherosclerosis are among the major causes of cardiac illness and death. Cardiovascular diseases are a major cause of disability and mortality world wide. According to the World Health Organization, 17 million people die every year from myocardial infarction and other cardiovascular diseases [4] . Annua lly, in Ukraine, about 50 000 people are esti mated to have acute myocardial infarction. Mortality statistics from this illness in Ukraine remains steadi ly high -30% of patients die from acute myocardial infarction, while in the Western countries -only 5% [5] .
Most of the hypolipidemic herbal medicines that used worldwide have excellent pharmacological propertieswithoutsideeffects.Naturalproductsare often attractive in medicinal chemistry because of their safety. In the last decade, many studies have focused on a variety of natural products used for the prevention and treatment of lipid metabolism disor ders. In these studies, phenolic compounds such asflavonoidshaveattractedgreatinterest,having pharmacological properties involved in efficient regulation of plasma lipids [6] . Flavonoids are a large group of naturally occurring compounds that are found in plants and are frequently consumed as part of the human diet. They are receiving much at tention nowadays for their potential pharmacologi cal properties, low toxicity, expressed antioxidant, anti-inflammatoryandotherpropertiesbeneficialfor human health [7] .
Quercetin(QUE)(3,3′,4′,5,7-pentahydroxyfla vone),acommonmemberoftheflavonoidfamily, is present widely in vegetables, fruits, tea, and red wine.Thisflavonoidactsasascavengerofsuper oxide and hydroxyl radicals or an inhibitor of lipid peroxidation and also possesses anti-inflammato ry, vasodilator effects, anti-hypercholesterolemic and antiatherosclerotic activities [8] . Recently, the findings ofSonHYetal.demonstratedthatQUE iseffectiveinregulatingCholmetabolism [9] .This substance has been characterized in several studies asaflavonolwithapotenthepatoprotectiveandan tifibroticpropertieswhichincreasesantioxidantca pacity and improves the functional status of the liver tissueaffectedbyvariousharmfulfactors [10, 11] . Littleinformationisavailableregardingtheinfluence of QUE on bile lipids. The study of the QUE ef fects in vivo is complicated by the low bioavailabili ty of this compound.
Сorvitinisawater-solubleanalogueofQUE with a similar biological and therapeutic activity. Unlike the QUE, corvitin dissolves readily in water and saline inducing a rapid response from the test organs after administration. In Ukraine, corvitin is used in clinical cardiology as a blocker of 5lipoxy genase activity in the treatment of coronary heart disease and myocardial infarction [12] . In our pre vious stu dies, we found that this drug increased tis suebloodflowinthegastricmucosaandliver [13] .In other studies, we observed the accelerated recovery oftissuebloodflowinthepancreas,gastricmucosa and liver of rats with acute pancreatitis following the treatment with corvitin [14] . In addition, recently, we have found that corvitin increased biliary content of both free and conjugated with amino acids BAs in rats depending on the tested doses [15] . The impact of corvitin on the hepatic formation and excretion of lipids in bile has not been investigated yet. The scheme of the experiment allowed us to estimate the effectofthetestfactorsindynamics.Inthisway, we could determine the latency of corvitininduced impact on the examined parameters and time inter valswhenthedrughadthegreatesteffectoncertain parameters of the lipid bile composition.
materials and methods
This study was conducted according to the de cision held by Biological Ethics Committee, Faculty ofBiology,NationalTarasSchevchenkoUniversity of Kyiv (protocol No 3 from April 9, 2009). This work has been done in accordance with European Convention for the protection of vertebrate animals usedforexperimentalandotherscientificpurposes (Strasbourg,1986),aswellas"Bioethicalexpertise of preclinical and other scientific researches con ducted on animals" (Kyiv, 2006) . Before starting the experiments, twenty six 12weekold mature male Wistar rats, weighing 220250 g were housed in a controlled environment (22 ± 2 °C, a relative humidi ty of 4555%, 12 h light/dark cycle), 6 animals per cage, with free access to food and tap water during the acclimatization period. Acute experiments were conducted after 18 h of fasting. Rats were randomly divided into 4 groups of 6 animals each. The rats were anesthetized with natrium thiopenta lum (Kyivmedpreparat, Ukraine, 4 mg/100 g, i.p.). Control animals (group I) were injected intrapor tally with a bolus of vehicle (sodium chloride 0.9%, 0.1 ml/100 g), whereas rats from model groups: II, III,andIVreceivedсorvitin2.5,5and10mg/kg, respectively, [13] in the same manner. Corvitin was supplied by the PJSC SIC Borshchahivskiy CPP (Kyiv, Ukraine). The purity of test samples was more than 99%. Anesthetized rats were subjected to laparotomy, and the common bile duct was cannu lated with a polyethylene catheter. All administra tions were performed after an equilibration period of30mintostabilizethebileflowrate.Secretedbile was collected every 30 min in the course of 2.5hour experiment by micropipette connected to a cannula, located in the bile duct. Bile lipids were separated by the method of thinlayer chromatography [16] . For this purpose, 0.1 ml of bile was added to 2.4 µl mix ture of chloroformmethanol (2 : 1), and 0.5 ml acidi fiedwater(0.5mlofconcentratedsulfuricacidper 1 liter of doubledistilled water) was added in 5 min. Sampleswerekeptovernightforcompleteseparation into two phases. The lower phase contained lipids. The extract was dried at 70 °C. The dry residue was dissolved in 40 µl of chloroformmethanol mixture (3 : 1) and put on the plate as a thin strip. Chroma tography was performed in a chamber, saturated by solvent vapor. The system of eluents included petro leum ether, diethyl ether, ether, glacial acetic acid (30 : 10 : 0.2). Fractions of biliary lipids were stained with 5% phosphomolybdic acid in 96% ethanol, fol lowedbyheatingat100°Cfor5min.Identification of the major lipid fractions was performed using standards and color of the spots, considering the relative mobility of fractions.
For quantitative evaluation of individual frac tions of lipids in bile, solutions of their main compo nents (1 mg of substance per 1 ml of solvent), both in dividually and in a mixture with specimens of other fractions, were prepared. This mixture of standards isquantitatively(from1μlto2;5;10;15;20;25and 30μl)adsorbedonchromatographicpaper.Afterex traction and concentration of bile at the bottom of the conetube,itshouldbedissolvedin50μlofsolvent anddroppedafewtimeswithamicropipette(5μl) on the surface of a prepared and marked chromato graphic plate. Chromatographic separation of lipid componentsofbilewascarriedoutonSilufolplates. After developing with an aqueous phosphomolybdic acid solution, quantitative estimation of color inten sity of each fraction was carried out with the use of densitometerDО-1М.Theareaofthespotwasalso measured. The value of the combined test is shown on the y axis of the calibration graph, and the xaxis is marked with the known amount of a correspon ding standard -a witness of the presen ce of this lipid fraction. These parameters were evaluated for frac tions of lipids from samples of the investigated bile. Based on the calibration curve, the amount of the correspondinglipidwasdeterminedinμg.Finally, taking into account the dilution and the part of the extract, we determined the amount of lipids in mg per 100 ml of bile.
The results were processed by oneway analysis of variance (ANOVA) followed by NewmanKeuls post hoc test. They were presented as mean ± the standarderrorofthemean±SEMandconsidered statisticallysignificantatP < 0.05. Observed power (alpha=0.05)was0.9.Themostpronouncedeffect ofcorvitinwasexpressedaspartialeta-squared(ŋ p 2 ), thevalueofwhichwasdefinedastheproportionof theeffect+errorvariancethatisattributabletothe effect.
results and discussion
Toinvestigatetheeffectofcorvitinonlipidex cretion, we treated laboratory rats with this drug and determined the changes in the content of lipids in the bile at each time point throughout the measurement period. It has been demonstrated that corvitin sig nificantlypromotedexcretionoflipidsfromtheliver into the bile. Hepatocytes directly uptake lipids from the blood with the help of microvilli. In the liver , the following processes of lipid metabolism take place: oxidation of TGs, formation of acetone bodies, syn thesis of TGs, PLs, lipoproteins, EChols and free Chol. The liver plays a central role in the regulation of Chol homeostasis. Chol enters the organ in the form of chylomicrons and lowdensity lipoproteins or is synthesized de novo from acetyl coenzyme A via a cascade of enzymatic reactions in which 3hy droxy3 methyl glutaryl CoA reductase (HMGCoA) is a key enzyme [17] . Chol is present in the liver in free form and the form of EChols. There are two ef fective ways to remove Chol from the body: the deg radation of the compound to BAs and their further secretion in bile; secretion in bile of the unchanged Chol [18] .
We found that in corvitintreated rats (2.5 mg/ kgofflavonoid)theamountoffreeCholwasnotsig nificantlyalteredinthefirst,inthesecond,andin the third halfhour samples. Meanwhile, this index wassignificantlyenhancedinthelasthouroftheex periment as compared with the control data ( Fig. 1 ).
Corvitin caused a marked increase in the fourth halfhour by 22.8% (P < 0.05), in the fifth -by 24.15% (P < 0.05). At a dose of 5 mg/kg corvitin, thelevelofCholwassignificantlyincreasedinthe third,inthefourthandinthefifthhalf-hoursam ples by 62.6% (P < 0.001), 57.3% (P < 0.001), 64.8% (P < 0.001), respectively. The output of Chol in re sponse to corvitin treatment at a dose of 10 mg/kg was higher than in the control rats during the fourth and the fifth half-hour by 40.2% (P < 0.001) and 39.4% (P < 0.001), respectively. Comparison of the Chol level in the bile among the groups showed that thedoseofcorvitin5mg/kgwasmosteffectivein stimulating the excretion of Chol from the liver into bile (Fig. 1) . The BAs synthesis provides a direct way of hydrophobic and insoluble Chol conversion into a watersoluble BA molecule, which is easily ex creted from the liver into bile immediately after the synthesis, with the bile entering the small intestine where it is reabsorbed and transported back to the liver [19] .
In our previous experiments, we observed that corvitin increased the volume of bile and biliary con centration of both total and individual BAs, that is, it enhances the conversion of the Chol to the BAs, accelerating its removal from the body in a liquid crystallineform [15] .Similarresultswereobtained by other authors in mice [20] and rats [21] . The rea sonforthiseffectwasthatQUEincreasedboththe expression of mRNA and the activity of cholesterol 7-α-hydroxylase(Cyp7α1)enzyme,whichisakey factor in the transformation of Chol into BAs [21] . On the other hand, there is evidence that QUE re ducesbloodlevelsofCholandTGs.Sucheffectmay beduetotheincreasedefficiencyofthetransport system, which uptakes Chol from the bloodstream and delivers it to hepatocytes [22] . In the present work, we found that QUE increases the secretion of free Chol. The latter is excreted in the intestine in micelles -the temporary structures, which include PLs and BAs along with Chol [23] . Thus, QUE pro motes the removal of Chol from the body through the liver involving both main ways. It is important for maintaining homeostasis of Chol in the body. Ex cessive accumulation of Chol in hepatocytes leads to damage of the liver, as the substance accumulates in the mitochondria, causing their dysfunction, which ultimately leads to complete loss of function of the cells and their death [24] . Bile, besides the free Chol, contains EChols and FFAs, which are a soluble form of Chol removal. We have found that the level of EChols in corvitintreated rats (2.5 mg/kg) was not significantlyalteredinthehalf-hoursamplesandin creased in the group of rats that received 5 mg/kg offlavonoidonlyinthethirdhalf-hoursampleby 55.2% (P < 0.05). The rats treated with corvitin at a dose of 10 mg/kg exhibited an increase in bilia ryECholseffluxinall2.5hoftheexperiment. fourth by 47.6% (P<0.05),andinthefifthby40% (P<0.05).So,themostsignificantincreasewasob served in the rats treated with corvitin at a dose of 10 mg/kg (Fig. 2) . Thepresenteddatashowthatcorvitinsignifi cantly increases the amount of Chol and its esters in 30-minbilesamples.Inparticular,significantchang es in the levels of Chol were found in response to all testeddosesofflavonoid,butcomparisonbetween differentexperimentalgroupsshowedthatthemaxi mum level of Chol in the bile was observed at a dose of corvitin 5 mg/kg. On the contrary, the Chol esteri ficationintheliverwasactivatedbycorvitindose of 10 mg/kg, because in this group of rats we found the highest amount of EChols in 30min samples of bile.Suchdataareinagreementwiththefindingsof our previous studies, where we have shown that a significantincreaseintheconcentrationofCholand ECholsinratbileoccursundertheeffectofcorvitin at doses of 5 and 10 mg/kg, respectively. In the lat ter case, there was a decrease in the ratio of Chol/ EChols , which was not observed in other groups EChols, a neutral lipids stored as droplets in the cell cytosol(theintracellularfluidenclosedbythecell membrane but not held within cellular organelles), allows for a non toxic method of excess cellular Chol storage. In the liver, uptake of Chol leads to an in crease in the amount of EChols within the cell that is dependent on the activity of cholesterolacyl trans ferase [26] . It should be noted that corvitin had the mostsignificantimpactontheproductionofFFAs, especially when it was used in a dose of 5 mg/kg. In this case, the bile content of FFAs increased almost twice. The secretion of FFAs in bile was enhanced in all three experimental groups of rats compared with thecontrolgroup.Significantchangeswereevident fromthefirsthalf-hourtowardtheendoftheexperi ment.Themostsignificantincreasewasobserved undertheeffectof5mg/kgcorvitininthethirdhalfhour by 78.8% (P < 0.001), in the fourth by 79.4% (P<0.001),inthefifthby90.3%(P < 0.001) as com pared with the results for the control group (Fig 3) . In animals, fatty acids have both an energy supplyingandamechanicalfunction.Somepartof the fatty acids that are present in the liver are de rivatives of cell membranes, but most of them are synthesized by liver cells de novo. A small amount of these compounds are involved in the secretion of both BAs and Chol into the bile [27] . As the level ofesterifiedCholincreasedundertheinfluenceof corvitin, we assumed that enhanced synthesis of fatty acids is a preparatory phase for activating the esterificationprocessesinhepatocytes.Thelatteris necessary for the synthesis of not only EChols but also PLs and TGs.
The level of PLs in all experimental groups in response to corvitin treatment was higher than in the control rats. At the dose of 2.5 mg/kg corvitin the ex cretion of PLs into bile increased in the third and in the fourth halfhour sample by 31.15% (P < 0.05) and by 31.2% (P < 0.05), respectively. Rats treated with corvitin at a dose of 5 mg/kg exhibited an increase inbiliaryPLseffluxin2 nd to 5 th halfhour samples (Fig.4) .Themostsignificantgrowthofthesesub stances in bile was observed in the third halfhour sample by 55.8% (P < 0.001), and in the fourth by 53.7% (P < 0.001). In our study, corvitin was also used at a dose of 10 mg/kg. As a result, it caused a significant increase in hepatic synthesis of PLs in experimental rats, and the level of bile PLs was markedlyincrementedinmostsampleswithsignifi cant deviations during 2 h in comparison with con trolrats.However,themostsignificantincreasewas observed in the fourth halfhour by 38.6% (P < 0.01) andinthefifthby36.1%(P < 0.01) as compared with the results in control rats (Fig. 4) . Bile PLs is com pletely synthesized de novo in the liver. Our results showedthatundertheinfluenceofcorvitintheexcre tion into the bile both PLs and TGs increased in all experimental groups. The level of bile PLs increased by more than 50% after the application of corvitin inadoseof5mg/kg(theeffectlastedthroughout the period of observation). In humans and animals, ThedeficiencyofPLsasacriticalcomponentforthe formation of micelles gradually leads to supersatura tion of bile with Chol and the formation of bile con crements [28] . Decreased production of PLs in the liver causes a disturbance in the formation of bile, which is the main mechanism for maintaining lipid homeostasis in the body [29] . In addition, as a result ofPLsdeficiency,thepermeabilityofthehepato cyte membrane and the accumulation of fat in liver increases because in the absence of PLs, the fatty acids (together with glycerol) form neutral fat that is accumulated in hepatocytes, displacing all other components [30] . Another important role of PLs is that by inhibiting the activity of collagenase, they prevent the synthesis of collagen, which is known to trigger the process of replacing epithelial tissue with the connective tissue [31] . Therefore, we believe that the observed increase in the synthesis of PLs by hepatocytesundertheinfluenceofcorvitinisaposi tive factor not only for stabilizing the colloidal sys tem of bile but also for preventing the accumulation offatinthelivertissueanddevelopmentoffibrosis.
According to our data, the TGs activity in creasedundertheeffectofcorvitin,comparedwith the control value in all experimental groups (Fig. 5) .
However, at a drug dose of 2.5 mg/kg, an in crease in TGs levels by 35% (P < 0.05) was noted only in the 5 th 30min bile assay. The level of TGs in bile increased in samples 25 after administration of 5 mg/kg corvitin to rats: in the 2 nd sample -by 32.6% (P < 0.05), in the 3 r d -by 36.4% (P < 0.05), in the 4 th -by 44% (P < 0.05), in the 5 th -by 49.9% (P < 0.05). After the application of 10 mg/kg of the drug, the TGs rate increased, similarly, in the sam ples 25 by 59.1% (P< 0.001), in the 3 rd -by 36.4% (P < 0.05), in the 4 th -by 50% (P < 0.05), in the 5 thby 47.2% (P < 0.05) ( Fig. 5 ). Recent studies provided strong evidence to support the concept that QUE af fects the liver lipogenesis, reducing the amount of TGs in the liver tissue and preventing fatty degene ration of the latter in mice. The authors emphasized thatthiseffectdependedonthedoseofQUEused (largerdosesweremoreeffectivethansmallones) [32] . In the mice fed with a highfat diet [33] , the QUE supplementation reduced liver fat content.
We concluded that corvitin modulates the quan titative composition of lipids in the bile of rats. The drugsignificantlypromotedtheexcretionofChol and its esters, PLs, TGs and FFAs from the liver to thebile.Inthedoseof5mg/kg,corvitinmosteffi ciently increased the content of Chol, PLs and FFAs, while 10 mg/kg of drug activated EChols and TGs synthesis. At a dose of 2.5 mg/kg, corvitin had a moderateeffectontheamountoflipidsinthebile of rats. Corvitin is suggested to be useful as a mono therapy or in combination with other drugs for the regulation of the synthesis of lipids in the liver and their excretion into bile to improve lipid ratio in bile. Кверцетин і його розчинна форма корві тин -важливі представники родини флавоної дівіхарчовіантиоксидантизнайзначноюдією. Численні фармакологічні ефекти кверцетину включають захист від таких захворювань, як атеросклероз, інфаркт міокарда та церебровас кулярні патології. Корвітин посилює кровотік упечінці,однакйоговпливназовнішньосекре торну функцію печінки до кінця не вивчено. Мидослідилиефекткорвітину(2,5;5і10мг/кг) на продукцію ліпідів у печінці щурів, зокрема на рівень у жовчі холестеролу (ХОЛ) і ефірів ХОЛ, фосфоліпідів (ФЛ), вільних жирних кис лот(ВЖК)татригліцеридів(TГ).Секретжовчі збирали протягом 2,5 год експерименту. Ліпід нікомпонентижовчірозділялиметодомтонко шарової хроматографії. Показано, що введення корвітинуспричинювалозначне(P < 0,05-0,001) підвищеннярівнявсіхдосліджуванихліпідних компонентівжовчі.Корвітинудозі2,5та5мг/кг збільшуваввмістжовчіщурівускладіХОЛ,ФЛ та ВЖК, а в дозі 10 мг/кг виявляв найбільший впливназагальнийоб'ємефірівХОЛтаТГ.Ми дійшли висновку, що корвітин активізує обмін ліпідівпечінкитапроцесиутворенняжовчі.
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